Parallax Behavioral Health, Inc.

Parallax Behavioral Health, Inc. is a wholly-owned subsidiary of Parallax Health Sciences, Inc. (OTC-Pink: PRLX), an innovative biomedical healthcare company headquartered in Santa Monica, California. Parallax Behavioral Health, Inc. was formed in September 2017 to address the growing behavioral health market. The parent company, Parallax Health Sciences, Inc., faced an SEC complaint in July 2021 for allegedly misleading investors about its ability to capitalize on the COVID-19 pandemic. No specific employee count or revenue figures are publicly available for the subsidiary.

Parallax Behavioral Health, Inc. focuses on proprietary solutions for the behavioral health sector. This includes its patent-pending R.E.B.O.O.T. technology, which incorporates predictive and progressive behavior analytics and goal optimization software, as well as a mobile app series called "MyPath." These offerings are designed to help large healthcare corporations and individuals manage their health outcomes.

Based on its patent litigation record, Parallax Behavioral Health, Inc. appears to be a non-practicing entity (NPE) asserting an acquired or internally developed patent portfolio. The company has a patent litigation posture as a plaintiff, with one tracked case and no appearances as a defendant. The sole case was filed in the Delaware District Court.

The company's only notable tracked case is Parallax Behavioral Health, Inc. v. Optum, Inc., filed on February 10, 2023, in the Delaware District Court. Optum, Inc. is a pharmacy benefit manager owned by UnitedHealth Group, which has publicly noted the impact of patent lawsuits on the adoption of biosimilar medications. The nature of the patent asserted by Parallax Behavioral Health, Inc. likely relates to its behavioral health technology, such as its remote patient monitoring and analytics platforms.